The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 24, 2015
Filed:
Aug. 21, 2013
Applicant:
Genentech, Inc., South San Francisco, CA (US);
Inventor:
Somasekar Seshagiri, San Carlos, CA (US);
Assignee:
Genentech, Inc., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); C12Q 1/48 (2006.01); G01N 33/574 (2006.01); A61K 31/19 (2006.01); A61K 31/498 (2006.01); A61K 31/517 (2006.01); A61K 31/704 (2006.01); A61K 31/7072 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 1/485 (2013.01); G01N 33/57492 (2013.01); A61K 31/19 (2013.01); A61K 31/498 (2013.01); A61K 31/517 (2013.01); A61K 31/704 (2013.01); A61K 31/7072 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/71 (2013.01); G01N 2500/00 (2013.01);
Abstract
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.